Spruce Biosciences, Inc. (SPRB)
SPRB moved a median of 0.00% 30 minutes after news, and -0.51% by the close. How SPRB actually reacts to news — the realized, point-in-time move the market made, measured across 449 labeled events over the last three years with zero look-ahead.
SPRB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 407 |
| 30-min | 0.00% | 47% | 439 |
| 60-min | -0.43% | 41% | 443 |
| to close | -0.51% | 43% | 441 |
| Middle 50% of SPRB reactions | -1.33% to +1.15% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 449 |
Half of all Spruce Biosciences, Inc. news events land between -1.33% and +1.15% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SPRB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -0.58% | 47% | +0.15% |
| Analyst downgrades | 24 | -4.35% | 21% | -29.51% |
| Coverage initiations | 23 | -0.14% | 44% | -3.33% |
| Rating reiterations | 50 | -0.20% | 42% | +0.91% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how SPRB ranks against every other measured name →
That’s how SPRB usually reacts — get an email when it moves on news →Email me when SPRB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SPRB's baseline. Nothing else.
Recent SPRB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference | Press release | Business Wire | -1.52% | -4.53% | |
| Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting | Press release | Business Wire | -1.02% | -2.39% | |
| Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | Business Wire | -0.09% | -4.75% | |
| Spruce Biosciences Announces Launch of MPS3BStudy.com | Press release | Business Wire | -1.01% | -4.68% | |
| Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026 | Press release | Business Wire | +0.00% | +9.63% | |
| Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences | Press release | Business Wire | -0.39% | +0.26% | |
| Form 10-Q SPRUCE BIOSCIENCES, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.39% | +0.26% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | +0.26% | |
| Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Press release | Business Wire | -0.39% | +0.26% | |
| Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development | Press release | Business Wire | -2.31% | +1.58% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.52% | |
| Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer | Press release | Business Wire | +0.00% | -1.52% | |
| Spruce Biosciences Joins the Russell 3000® Index | Press release | Business Wire | +0.00% | +1.29% | |
| Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs | Press release | Business Wire | +0.84% | +5.09% | |
| Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller | Press release | Business Wire | +0.00% | -3.64% | |
| Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium | Press release | Business Wire | +0.55% | -3.33% | |
| Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium | Press release | Business Wire | -0.59% | +4.19% | |
| Spruce Biosciences to Participate in Upcoming Conferences in June | Press release | Business Wire | -1.55% | -2.27% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.09% | |
| Form 10-Q SPRUCE BIOSCIENCES, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.00% | +1.88% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.38% | |
| Form S-8 SPRUCE BIOSCIENCES, INC. | SEC filing · Form S-8 | SEC EDGAR | +1.00% | +1.88% | |
| Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Press release | Business Wire | +0.00% | +3.38% | |
| Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations | Press release | Business Wire | +0.00% | +5.06% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -1.55% | -7.74% | |
| Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | Press release | Business Wire | -1.55% | -10.88% | |
| Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | Business Wire | -1.55% | -10.88% | |
| Form ARS SPRUCE BIOSCIENCES, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -3.22% | |
| Form DEF 14A SPRUCE BIOSCIENCES, INC. For: Apr 09 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -3.22% | |
| Form DEFA14A SPRUCE BIOSCIENCES, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -3.22% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -1.67% | -3.90% | |
| Form 10-K SPRUCE BIOSCIENCES, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +18.37% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +18.37% | |
| Form S-8 SPRUCE BIOSCIENCES, INC. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +18.37% | |
| Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer | Press release | Business Wire | +0.00% | +18.37% | |
| Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates | Press release | Business Wire | +0.00% | +18.37% | |
| Spruce Biosciences to Present at Upcoming Investor Conferences in March | Press release | Business Wire | +0.00% | — | |
| Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) | Press release | Business Wire | -0.41% | -11.98% | |
| Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | Business Wire | -0.41% | -11.98% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | +2.93% | +1.73% | |
| Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) | Press release | Business Wire | +2.93% | +1.73% | |
| Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team | Press release | Business Wire | -1.22% | +5.74% | |
| Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ | Press release | Business Wire | +1.25% | -2.50% | |
| Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration | Press release | PR Newswire | -0.57% | -2.74% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -9.26% | |
| Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital | Press release | Business Wire | +0.00% | -9.26% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.50% | |
| Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors | Press release | Business Wire | +0.00% | -3.50% | |
| Form 8-K SPRUCE BIOSCIENCES, INC. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.50% | |
| Form EFFECT SPRUCE BIOSCIENCES, INC. | SEC filing · Form EFFECT | SEC EDGAR | -0.14% | -9.91% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SPRB section they belong to.
Where else SPRB is measured.
SPRB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Spruce Biosciences, Inc.'s median reaction calculated?
Every labeled SPRB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 449 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of SPRB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SPRB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.